Database : MEDLINE
Search on : Lymphatic and Vessel and Tumors [Words]
References found : 2550 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 255 go to page                         

  1 / 2550 MEDLINE  
              next record last record
select
to print
Photocopy

[PMID]: 29374693
[Au] Autor:Ernst BP; Mikstas C; Stöver T; Stauber R; Strieth S
[Ad] Address:Department of Otorhinolaryngology, University Hospital Frankfurt, Frankfurt, Germany benjamin.ernst@unimedizin-mainz.de.
[Ti] Title:Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer.
[So] Source:Anticancer Res;38(2):699-706, 2018 02.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:BACKGROUND/AIM: Head and neck squamous cell carcinomas (HNSCC) are characterized by aggressiveness, early recurrence and lymph node metastasis. Therefore, there is an urgent need to identify new biomarkers and drug targets. MATERIALS AND METHODS: Neck dissection specimens from 11 patients diagnosed with hypopharyngeal cancer were analyzed for their lymphatic vessel density (LVD) by lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) immunostaining, expression of eukaryotic initiation factor 4E (eIF4E) and levels of secreted protein acidic and rich in cysteine (SPARC) using immunoblot analysis. RESULTS: Compared to lymph node biopsies of healthy controIs, LVD was significantly increased in metastatic lymph nodes as well as in advanced primary tumors. Overexpression of eIF4E and SPARC was demonstrated in all hypopharyngeal cancer specimens. Notably, we observed that increased LVD significantly correlated with the expression of eIF4E as well as SPARC levels. CONCLUSION: eIF4E- and SPARC-associated signaling pathways may be associated with lymphangiogenesis and could be exploited to counteract the spread of hypopharyngeal cancer cells.
[Mh] MeSH terms primary: Hypopharyngeal Neoplasms/metabolism
Hypopharyngeal Neoplasms/pathology
Lymphangiogenesis/physiology
Nucleocytoplasmic Transport Proteins/metabolism
Osteonectin/metabolism
[Mh] MeSH terms secundary: Biomarkers, Tumor/metabolism
Carcinoma, Squamous Cell/metabolism
Carcinoma, Squamous Cell/pathology
Female
Head and Neck Neoplasms/metabolism
Head and Neck Neoplasms/pathology
Humans
Lymph Nodes/metabolism
Lymph Nodes/pathology
Lymphatic Metastasis/pathology
Male
Middle Aged
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (EIF4ENIF1 protein, human); 0 (Nucleocytoplasmic Transport Proteins); 0 (Osteonectin); 0 (SPARC protein, human)
[Em] Entry month:1802
[Cu] Class update date: 180208
[Lr] Last revision date:180208
[Js] Journal subset:IM
[Da] Date of entry for processing:180129
[St] Status:MEDLINE

  2 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29374745
[Au] Autor:Luczynska E; Niemiec J; Heinze S; Adamczyk A; Ambicka A; Marcyniuk P; Rudnicki W; Mitus JW; Dyczek S; Rys J; Sas-Korczynska B
[Ad] Address:Department of Radiology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow, Poland.
[Ti] Title:Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
[So] Source:Anticancer Res;38(2):1085-1095, 2018 02.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:BACKGROUND/AIM: It is possible that the degree of enhancement on contrast-enhanced spectral mammography (CESM), a new diagnostic method, might provide prognostic information for breast cancer patients. Therefore, in a group of 82 breast cancer patients, we analyzed the prognostic significance of degree and pattern of enhancement on CESM as well as its relation to: (a) breast cancer immunophenotype (based on ER/PR/HER2 status) (b) podoplanin expression in cancer stroma (lymphatic vessel density plus podoplanin-positivity of cancer-associated fibroblasts), and (c) other histological parameters. MATERIALS AND METHODS: For each tumor the intensity of enhancement on CESM was qualitatively assessed as strong or weak/medium, while the pattern - as homogenous and heterogenous. RESULTS: Herein we report, for the first time, that strong and heterogenous enhancement on CESM was related to unfavorable disease-free survival of breast cancer patients (p=0.005). Moreover, the strong enhancement was more frequent in large and node-positive tumors (pT>1, pN>0) (p=0.002), as well as in carcinomas with podoplanin-sparse stroma (p=0.008). CONCLUSION: Intensity and pattern of enhancement on CESM might provide (together with the results of other diagnostic imaging methods) not only the confirmation of presence or absence of tumor, but also prognostic information.
[Mh] MeSH terms primary: Biomarkers, Tumor/metabolism
Breast Neoplasms/pathology
Contrast Media
Magnetic Resonance Imaging/methods
Membrane Glycoproteins/metabolism
Stromal Cells/metabolism
[Mh] MeSH terms secundary: Adenocarcinoma, Mucinous/metabolism
Adenocarcinoma, Mucinous/pathology
Adenocarcinoma, Mucinous/therapy
Breast Neoplasms/metabolism
Breast Neoplasms/therapy
Cancer-Associated Fibroblasts
Carcinoma, Ductal, Breast/metabolism
Carcinoma, Ductal, Breast/pathology
Carcinoma, Ductal, Breast/therapy
Carcinoma, Lobular/metabolism
Carcinoma, Lobular/pathology
Carcinoma, Lobular/therapy
Carcinoma, Papillary/metabolism
Carcinoma, Papillary/pathology
Carcinoma, Papillary/therapy
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Mammography
Middle Aged
Prognosis
Retrospective Studies
Stromal Cells/pathology
Survival Rate
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (Contrast Media); 0 (Membrane Glycoproteins); 0 (PDPN protein, human)
[Em] Entry month:1802
[Cu] Class update date: 180207
[Lr] Last revision date:180207
[Js] Journal subset:IM
[Da] Date of entry for processing:180129
[St] Status:MEDLINE

  3 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29282520
[Au] Autor:Bauer J; Rothley M; Schmaus A; Quagliata L; Ehret M; Biskup M; Orian-Rousseau V; Jackson DG; Pettis RJ; Harvey A; Bräse S; Thiele W; Sleeman JP
[Ad] Address:Karlsruhe Institute for Technology (KIT), Institute of Toxicology and Genetics, Postfach 3640, 76021, Karlsruhe, Germany.
[Ti] Title:TGFß counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides.
[So] Source:J Mol Med (Berl);96(2):199-209, 2018 Feb.
[Is] ISSN:1432-1440
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:During tissue injury, inflammation, and tumor growth, enhanced production and degradation of the extracellular matrix glycosaminoglycan hyaluronan (HA) can lead to the accumulation of small HA (sHA) oligosaccharides. We have previously reported that accumulation of sHA in colorectal tumors correlates with lymphatic invasion and lymph node metastasis, and therefore, investigated here are the effects of sHA on the lymphatic endothelium. Using cultured primary lymphatic endothelial cells (LECs) and ex vivo and in vivo lymphangiogenesis assays, we found that in contrast to high-molecular-weight HA (HMW-HA), sHA of 4-25 disaccharides in length can promote the proliferation of LECs and lymphangiogenesis in a manner that is dependent on their size and concentration. At pathophysiologically relevant concentrations found in tumor interstitial fluid, sHA is pro-proliferative, acts synergistically with VEGF-C and FGF-2, and stimulates the outgrowth of lymphatic capillaries in ex vivo lymphangiogenesis assays. In vivo, intradermally injected sHA acts together with VEGF-C to increase lymphatic vessel density. Higher concentrations of sHA were found to induce expression of the anti-lymphangiogenic cytokine TGFß in LECs, which serves to counter-regulate sHA-induced LEC proliferation and lymphangiogenesis. Using appropriate knockout mice and blocking antibodies, we found that the effects of sHA are mediated by the sialylated form of the lymphatic HA receptor LYVE-1, but not by CD44 or TLR-4. These data are consistent with the notion that accumulation of sHA in tumors may contribute to tumor-induced lymphangiogenesis, leading to increased dissemination to regional lymph nodes. KEY MESSAGES : sHA promotes lymphangiogenesis primarily through increased LEC proliferation sHA induces proliferation in a narrow concentration window due to upregulated TGFß Smaller HA oligosaccharides more potently induce proliferation than larger ones VEGF-C and FGF-2-induced LEC proliferation and lymphangiogenesis is augmented by sHA Sialylated LYVE-1, but not CD44 or TLR-4, mediate the effects of sHA on LEC.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180129
[Lr] Last revision date:180129
[St] Status:In-Data-Review
[do] DOI:10.1007/s00109-017-1615-4

  4 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28741534
[Au] Autor:Wendler F; Stamp GW; Giamas G
[Ad] Address:University of Sussex, School of Life Sciences, John Maynard Smith Building, Falmer, Brighton BN1 9QG, UK. Electronic address: f.wendler@sussex.ac.uk.
[Ti] Title:Tumor-Stromal Cell Communication: Small Vesicles Signal Big Changes.
[So] Source:Trends Cancer;2(7):326-329, 2016 Jul.
[Is] ISSN:2405-8025
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Reciprocal interactions between malignant and stromal cells create a local microenvironment that fosters tumor growth. Extracellular vesicles (EVs) such as exosomes, microvesicles, and large oncosomes are involved in tumor-stroma communication by shuttling signaling cargo and other molecules. Here we discuss how EVs released by cancer or stromal cells impact the proliferation, differentiation, and metabolism of tumors.
[Mh] MeSH terms primary: Extracellular Vesicles/pathology
Neoplasms/pathology
Stromal Cells/pathology
Tumor Microenvironment
[Mh] MeSH terms secundary: Animals
Fibroblasts
Lymphatic Vessels
Neoplasms/immunology
Signal Transduction
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180125
[Lr] Last revision date:180125
[Js] Journal subset:IM
[Da] Date of entry for processing:170726
[St] Status:MEDLINE

  5 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29183000
[Au] Autor:van Netten JP; Cann SH; Thornton IG; Finegan RP
[Ad] Address:University of Victoria, Canada. Electronic address: jpvannetten@shaw.ca.
[Ti] Title:The lymphatics in infiltrating ductal carcinoma (IDC) of the breast.
[So] Source:Cancer Treat Rev;62:97, 2018 01.
[Is] ISSN:1532-1967
[Cp] Country of publication:Netherlands
[La] Language:eng
[Mh] MeSH terms primary: Breast Neoplasms
Lymphatic Vessels
[Mh] MeSH terms secundary: Carcinoma, Ductal
Humans
[Pt] Publication type:JOURNAL ARTICLE; REVIEW; COMMENT
[Em] Entry month:1801
[Cu] Class update date: 180119
[Lr] Last revision date:180119
[Js] Journal subset:IM
[Da] Date of entry for processing:171129
[St] Status:MEDLINE

  6 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29350326
[Au] Autor:Liu Y; Ren W; Bai Y; Wan L; Sun X; Liu Y; Xiong W; Zhang YY; Zhou L
[Ad] Address:Department of Pharmacology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, 3-17 Renmin South Road, Chengdu, 610041, Sichuan, People's Republic of China.
[Ti] Title:Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis.
[So] Source:J Nat Med;, 2018 Jan 19.
[Is] ISSN:1861-0293
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:The purpose of this study was to investigate the effects and mechanisms of oxyresveratrol (Oxyres) on hepatocellular carcinoma (HCC) in vitro and in vivo. The MTT and Transwell assays were performed to investigate the effects of Oxyres on cell proliferation and migration of two HCC cell lines, QGY-7701 and SMMC-7721 cells. H22 cells were subcutaneously injected into hind foot pads of 70 male mice to establish a lymph node metastasis model. These mice were randomly divided into seven groups as follows, control group, HCC group, Oxyres 20 mg/kg group, Oxyres 40 mg/kg group, Oxyres 60 mg/kg group, Resveratrol (Res) group, and Adriamycin (ADM) group. Oxyres, Res, and ADM were intraperitoneally injected daily for consecutive 21 days. Tumors and popliteal lymph node were isolated and embedded for histology analysis. Expressions of CD31 and vascular endothelial growth factor receptor-3 (VEGFR3) in tumors were detected by immunohistocehmistry. Expressions of vascular endothelial growth factor C (VEGF-C) were measured by Western blot. Oxyres significantly inhibited the proliferation and migration of QGY-7701 and SMMC-7721 cells. Oxyres significantly inhibited tumor growth (p < 0.001) and metastasis to sentinel lymph nodes (70%) in a dose-dependent manner. Oxyres showed a similar inhibition rate as Res. Oxyres also significantly decreased micro-blood vessel density and micro-lymphatic vessel density in tumors (p < 0.05). Expressions of CD31, VEGFR3, and VEGF-C of tumors were also inhibited by Oxyres (p < 0.05). Oxyres exerts anti-tumor effects against HCC through inhibiting both angiogenesis and lymph node metastasis, which suggests Oxyres be a potential therapeutic agent.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180119
[Lr] Last revision date:180119
[St] Status:Publisher
[do] DOI:10.1007/s11418-018-1173-2

  7 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28741486
[Au] Autor:Lund AW
[Ad] Address:Department of Cell, Developmental, & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: lunda@ohsu.edu.
[Ti] Title:Rethinking Lymphatic Vessels and Antitumor Immunity.
[So] Source:Trends Cancer;2(10):548-551, 2016 Oct.
[Is] ISSN:2405-8025
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Lymphatic vessels facilitate fluid homeostasis, immune cell trafficking, and lipid transport, and contribute to solid tumor progression as routes of metastasis. Given new evidence that lymphatic vessels both correlate with intratumoral lymphocytes and directly suppress immune function, I reevaluate the passive lymphatic vessel paradigm and discuss its relevance to antitumor immunity.
[Mh] MeSH terms primary: Lymphatic Vessels/immunology
Neoplasms/immunology
[Mh] MeSH terms secundary: Animals
Endothelial Cells/immunology
Humans
Lymphatic Metastasis
Neoplasms/pathology
T-Lymphocytes/immunology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180118
[Lr] Last revision date:180118
[Js] Journal subset:IM
[Da] Date of entry for processing:170726
[St] Status:MEDLINE

  8 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29277762
[Au] Autor:Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
[Ad] Address:Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori University Faculty of Medicine, Yonago, Japan sai10@med.tottori-u.ac.jp.
[Ti] Title:Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
[So] Source:Anticancer Res;38(1):107-112, 2018 01.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:BACKGROUND: A recent study demonstrated that immune-checkpoint molecules are associated with tumoral immune evasion. MATERIALS AND METHODS: Programmed cell death protein 1 (PD-1) expression on CD4 and CD8 T-cells obtained from gastric cancer tissue was evaluated by multicolor flow cytometry. Immunohistochemical staining was also performed to evaluate programmed cell death ligand-1 (PD-L1) expression on gastric cancer cells. RESULTS: There were statistically significant correlations between PD-L1 expression and age, histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, venous invasion, and disease stage. The 5-year survival rates of patients with and without PD-L1-positive tumors were 48.9% and 80.7%, respectively, and the difference was statistically significant. Multivariate analysis indicated that PD-L1 expression was an independent prognostic indicator. The frequency of PD-1-positive CD4 and CD8 T-cells from gastric cancer tissue with PD-L1 expression was significantly more than that from gastric cancer tissue without PD-L1 expression. CONCLUSION: PD-L1 expression was related to a poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on T-cells was up-regulated in patients with tumors with PD-L1 expression.
[Mh] MeSH terms primary: B7-H1 Antigen/metabolism
Programmed Cell Death 1 Receptor/metabolism
Stomach Neoplasms/metabolism
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
CD4-Positive T-Lymphocytes/metabolism
CD8-Positive T-Lymphocytes/metabolism
Female
Humans
Male
Middle Aged
Prognosis
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (B7-H1 Antigen); 0 (CD274 protein, human); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor)
[Em] Entry month:1801
[Cu] Class update date: 180104
[Lr] Last revision date:180104
[Js] Journal subset:IM
[Da] Date of entry for processing:171227
[St] Status:MEDLINE

  9 / 2550 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29243194
[Au] Autor:Ma C; Luo C; Yin H; Zhang Y; Xiong W; Zhang T; Gao T; Wang X; Che D; Fang Z; Li L; Xie J; Huang M; Zhu L; Jiang P; Qi W; Zhou T; Yang Z; Wang W; Ma J; Gao G; Yang X
[Ad] Address:Program of Molecular Medicine, Affiliated Guangzhou Women and Children's Hospital, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
[Ti] Title:Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion.
[So] Source:Gastric Cancer;, 2017 Dec 14.
[Is] ISSN:1436-3305
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:BACKGROUND: Tumor-induced lymphangiogenesis and lymphatic metastasis are predominant during the metastasis of many types of cancers. However, the endogenous inhibitors that counterbalance the lymphangiogenesis and lymphatic metastasis of tumors have not been well evaluated. Kallistatin has been recognized as an endogenous angiogenesis inhibitor. METHODS AND RESULTS: Our recent study showed for the first time that the lymphatic vessel density (LVD) was reduced in lung and stomach sections from kallistatin-overexpressing transgenic mice. Kallistatin expresses anti-lymphangiogenic activity by inhibiting the proliferation, migration, and tube formation of human lymphatic endothelial cells (hLECs). Therefore, the present study focuses on the relationships of changes in kallistatin expression with the lymphangiogenesis and lymphatic metastasis of gastric cancer and its underlying mechanisms. Our results revealed that the expression of kallistatin in cancer tissues, metastatic lymph nodes, and plasma of gastric cancer patients was significantly downregulated and that the plasma level of kallistatin was negatively associated with the phase of lymph node metastasis. Furthermore, treatment with kallistatin recombinant protein decreased LVD and lymph node metastases in the implanted gastric xenograft tumors of nude mice. Mechanically, kallistatin suppressed the lymphangiogenesis and lymphatic metastasis by downregulating VEGF-C expression and secretion through the LRP6/IKK/IÒ¡B/NF-Ò¡B signaling pathway in gastric cancer cells. CONCLUSIONS: These findings demonstrated that kallistatin functions as an endogenous lymphangiogenesis inhibitor and has an important part in the lymphatic metastasis of gastric cancer.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 171215
[Lr] Last revision date:171215
[St] Status:Publisher
[do] DOI:10.1007/s10120-017-0787-5

  10 / 2550 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 29178101
[Au] Autor:Zhou R; Zhao J; Shu P; Wang H; Qin J; Sun Y
[Ti] Title:[Clinicopathologic characteristics and prognosis analysis of 90 young patients with gastric cancer].
[So] Source:Zhonghua Wei Chang Wai Ke Za Zhi;20(11):1288-1292, 2017 Nov 25.
[Is] ISSN:1671-0274
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To investigate the features of clinicopathology and prognosis in young gastric cancer patients. METHODS: Clinicopathological data of 90 young gastric cancer patients (≤40 years old) who received radical gastrectomy in the Department of General Surgery of Zhongshan Hospital, Fudan University from January 2013 to December 2014 were retrospectively analyzed. Survival data were obtained by follow-up and the last follow-up time was October 2016. Log-rank test and Cox regression model were used to analyze the risk factors of prognosis and these factors included gender, age, tumor size, degree of differentiation, histological type, Lauren pattern, T stage, N stage, vessel carcinoma embolus, clinical symptom, anemic condition, CA19-9 level, et al. RESULTS: The median age of 90 patients was 35 years old, of whom, 20(22.2%) patients were ≤30 years old and 70(77.8%) patients were between 31 and 40 years old. There were 70(77.8%) female patients, 38(42.2%) patients with anemia, 11(12.8%) patients with elevated CA19-9 level and 9(10.0%) patients with family history of gastrointestinal tumors. The mean time of all the patients from presence of symptom to consultation was 8.2 months. Postoperative pathology revealed 65(72.2%) patients with poorly differentiated adenocarcinoma, 6(6.7%) patients with mucinous adenocarcinoma, 9(10%) patients with signet-ring cell carcinoma, and 10(11.1%) patients with papillary-canalicular adencarcinoma. Sixty-nine (76.7%) patients were diagnosed as advanced gastric cancer and 67(74.4%) patients were involved with lymphatic metastasis when they visited our hospital. Univariate analysis showed that gender (P=0.021), tumor size (P=0.001), depth of tumor infiltration (P=0.016), lymphatic metastasis (P=0.000), vessel carcinoma embolus (P=0.001), elevated CA19-9 level (P=0.001), and anemia (0.024) were statistically related with postoperative survival. Multivariate analysis showed that lymphatic metastasis was an independent risk factor of the poor prognosis of young patients (HR:2.774, 95%CI:1.435 to 5.364, P=0.002). CONCLUSIONS: The majority of young gastric cancer cases are female with poorly differentiated adenocarcinoma. Most patients are diagnosed as advanced gastric cancer with lymphatic metastasis when they visit hospital at the first time. The lymphatic metastasis is an independent risk factor of prognosis in young gastric cancer patients.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171127
[Lr] Last revision date:171127
[St] Status:In-Process


page 1 of 255 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information